Investigational drug · Phase 3
BL-8040
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Pancreatic Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
19
Any phase or sponsor naming "BL-8040"
First trial start
2017
Jul 5, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL-8040", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Multiple myeloma · Oncology · Hematology and blood cancers · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BL-8040" as an intervention, largest first.
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03193190 · 341 participants · Start Jul 5, 2017 · Primary completion Feb 27, 2025
Drug: Nab-Paclitaxel; Gemcitabine and 13 more · For: Pancreatic Adenocarcinoma
Sites: Duarte, California; San Francisco, California; New Haven, Connecticut · 23 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03281369 · 219 participants · Start Oct 13, 2017 · Primary completion Oct 9, 2025
Drug: 5-Fluorouracil (5-FU); Leucovorin and 13 more · For: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Sites: Scottsdale, Arizona; Los Angeles, California; Santa Monica, California · 28 sites in all
- BL-8040 Addition to Consolidation Therapy in AML PatientsPivotal-lookingStatus unknown
Dr. Petra TschanterAcademic, hospital or other
NCT02502968 · 194 participants (planned) · Start Sep 2015 · Primary completion Jul 2018
Drug: Cytarabine; BL-8040 and 1 more · For: Acute Myeloid Leukemia
Sites: Halle, Germany
- A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)Pivotal-lookingActive, not recruiting
BioLineRx, Ltd.Industry
NCT03246529 · 180 participants · Start Mar 23, 2018 · Primary completion Dec 22, 2020
Drug: BL-8040 1.25 mg/kg + G-CSF; Placebo +G-CSF · For: Multiple Myeloma
Sites: Los Angeles, California; Gainesville, Florida; Miami, Florida · 18 sites in all
- Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaActive, not recruiting
Columbia UniversityAcademic, hospital or other
NCT04543071 · 118 participants (planned) · Start Nov 9, 2020 · Primary completion Jun 2028
Drug: Motixafortide; Cemiplimab and 2 more · For: Pancreatic Cancer; Adenocarcinoma of the Pancreas; Adenocarcinoma
Sites: Boston, Massachusetts; New York, New York; Providence, Rhode Island · 5 sites in all
Emory UniversityAcademic, hospital or other
NCT07101445 · 94 participants (planned) · Start Sep 24, 2025 · Primary completion Dec 31, 2026
Drug: Acetaminophen; Dexamethasone and 6 more · For: Multiple Myeloma
Sites: Atlanta, Georgia
BioLineRx, Ltd.Industry
NCT02826486 · 80 participants · Start Sep 2016 · Primary completion Sep 6, 2022
Drug: BL-8040; Pembrolizumab and 1 more · For: Metastatic Pancreatic Adenocarcinoma
Sites: Phoenix, Arizona; Scottsdale, Arizona; New Orleans, Louisiana · 31 sites in all
- Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsPivotal-lookingRecruiting
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT06514508 · 60 participants (planned) · Start Dec 1, 2025 · Primary completion Sep 11, 2026
Drug: Motixafortide+G-CSF; Placebo+G-CSF · For: Multiple Myeloma
Sites: Beijing, China; Harbin, China
Washington University School of MedicineAcademic, hospital or other
NCT02639559 · 50 participants · Start Mar 31, 2016 · Primary completion Apr 12, 2018
Drug: BL-8040 · For: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia and 8 more
Sites: Atlanta, Georgia; St Louis, Missouri; Columbus, Ohio
- Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsCompleted
BioLineRx, Ltd.Industry
NCT01838395 · 42 participants · Start Apr 2013 · Primary completion Mar 2016
Drug: Ara-C; BL-8040 · For: Acute Myeloid Leukemia
Sites: Jacksonville, Florida; Baltimore, Maryland; St Louis, Missouri · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Theranostic applications of CXCR4-targeted imaging ligands in lymphoma: integrating diagnosis and precision therapy.
Dhamecha KR, Booth OC, Oderinde OM, et al. · Am J Nucl Med Mol Imaging 2026
- Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma.
Raufi AG, Pellicciotta I, Palermo CF, et al. · bioRxiv 2023
- Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.
Rebolledo-Bustillo M, Garcia-Gomez D, Dávila EM, et al. · Int J Mol Sci 2023
- Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors.
Xiang J, Shi M, Fiala MA, et al. · Blood Adv 2022
- At the Bedside: Profiling and treating patients with CXCR4-expressing cancers.
Martin M, Mayer IA, Walenkamp AME, et al. · J Leukoc Biol 2021
- BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Borthakur G, Ofran Y, Tallman MS, et al. · Cancer 2021
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.